Wound-Microenvironment Engineering through Advanced-Dressing Bioprinting.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
04 Mar 2022
Historique:
received: 09 02 2022
revised: 23 02 2022
accepted: 02 03 2022
entrez: 10 3 2022
pubmed: 11 3 2022
medline: 9 4 2022
Statut: epublish

Résumé

In patients with comorbidities, a large number of wounds become chronic, representing an overwhelming economic burden for healthcare systems. Engineering the microenvironment is a paramount trend to activate cells and burst-healing mechanisms. The extrusion bioprinting of advanced dressings was performed with novel composite bioinks made by blending adipose decellularized extracellular matrix with plasma and human dermal fibroblasts. Rheological and microstructural assessments of the composite hydrogels supported post-printing cell viability and proliferation over time. Embedded fibroblasts expressed steady concentrations of extracellular matrix proteins, including type 1, 3 and 4 collagens and fibronectin. ELISA assessments, multiplex protein arrays and ensuing bioinformatic analyses revealed paracrine activities corresponding to wound-healing activation through the modulation of inflammation and angiogenesis. The two modalities of advanced dressings, differing in platelet number, showed differences in the release of inflammatory and angiogenic cytokines, including interleukin 8 (IL-8), monocyte chemotactic protein 1 (MCP-1), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF). The conditioned media stimulated human-dermal-cell proliferation over time. Our findings open the door to engineering the microenvironment as a strategy to enhance healing.

Identifiants

pubmed: 35269978
pii: ijms23052836
doi: 10.3390/ijms23052836
pmc: PMC8911091
pii:
doi:

Substances chimiques

Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Basque Government
ID : Program Elkartek B4H KK-2019-0006-BC

Références

Bioact Mater. 2021 Sep 22;10:236-246
pubmed: 34901542
Int Wound J. 2022 Feb;19(2):389-398
pubmed: 34169656
Cell Transplant. 2014 Jan;23(1):39-49
pubmed: 23211390
Biomaterials. 2019 Sep;216:119267
pubmed: 31247480
J Wound Care. 2014 Nov;23(11):521-2, 524, 526-30
pubmed: 25375400
Macromol Biosci. 2018 Oct;18(10):e1800167
pubmed: 30156756
Regen Med. 2013 Sep;8(5):645-58
pubmed: 23998756
Int J Mol Sci. 2020 Jan 17;21(2):
pubmed: 31963580
Adv Healthc Mater. 2020 Aug;9(15):e1901648
pubmed: 32352649
Front Bioeng Biotechnol. 2019 Dec 03;7:371
pubmed: 31921799
Nature. 2019 Oct;574(7779):553-558
pubmed: 31645721
Bioact Mater. 2021 Jul 05;8:296-308
pubmed: 34541402
ACS Appl Mater Interfaces. 2020 Mar 18;12(11):12557-12572
pubmed: 32092249
Adv Mater. 2022 Jan;34(2):e2103691
pubmed: 34672027
J Clin Med. 2022 Jan 18;11(3):
pubmed: 35159924
Lancet Diabetes Endocrinol. 2018 Nov;6(11):870-878
pubmed: 30243803
Nanomaterials (Basel). 2020 Jun 25;10(6):
pubmed: 32630377
Ann Surg. 1986 Sep;204(3):322-30
pubmed: 3753059
Biofabrication. 2016 Dec 05;9(1):015006
pubmed: 27917823
J Invest Dermatol. 2008 Oct;128(10):2526-40
pubmed: 18449211
Br J Dermatol. 2015 Aug;173(2):370-8
pubmed: 26175283
Adv Wound Care (New Rochelle). 2015 Sep 1;4(9):534-544
pubmed: 26339532
J Foot Ankle Surg. 2002 Sep-Oct;41(5):291-9
pubmed: 12400712
Mater Today Bio. 2021 Dec 11;13:100188
pubmed: 34977527
Adv Wound Care (New Rochelle). 2012 Jun;1(3):138-141
pubmed: 24527294
Int J Mol Sci. 2021 Apr 08;22(8):
pubmed: 33917732
Burns. 2003 Dec;29(8):837-41
pubmed: 14636761
Sci Rep. 2019 Feb 12;9(1):1856
pubmed: 30755653
Front Endocrinol (Lausanne). 2020 Sep 16;11:573032
pubmed: 33042026
Biomaterials. 2017 Mar;120:66-80
pubmed: 28038353
Acta Biomater. 2013 Dec;9(12):9351-9
pubmed: 23917148
Adv Skin Wound Care. 2011 Jul;24(7):306-11
pubmed: 21685733
Int J Mol Sci. 2020 Sep 12;21(18):
pubmed: 32932676
J Plast Reconstr Aesthet Surg. 2021 Nov;74(11):2821-2830
pubmed: 34246590
Micromachines (Basel). 2021 Feb 13;12(2):
pubmed: 33668565
Front Bioeng Biotechnol. 2021 Sep 20;9:718377
pubmed: 34616718
Int Wound J. 2017 Apr;14(2):322-330
pubmed: 27229943
PLoS One. 2014 Mar 11;9(3):e91574
pubmed: 24618995
J Am Col Certif Wound Spec. 2011 Sep;3(3):65-6
pubmed: 24525756
J Tissue Eng. 2022 Jan 6;13:20417314211063022
pubmed: 35024135
Exp Cell Res. 1995 May;218(1):381-8
pubmed: 7737374
Biomedicines. 2021 Aug 16;9(8):
pubmed: 34440227
Biomedicines. 2020 Oct 21;8(10):
pubmed: 33096771
Curr Tissue Microenviron Rep. 2020 Sep;1(3):73-87
pubmed: 33748773
J Biomater Sci Polym Ed. 2021 Nov 21;:1-21
pubmed: 34779715
Ann Plast Surg. 2019 Dec;83(6):e96-e109
pubmed: 31335465
Ann Transl Med. 2016 Dec;4(23):457
pubmed: 28090513
Methods. 2020 Jan 15;171:97-107
pubmed: 31051252
Methods. 2015 Aug;84:25-34
pubmed: 25791470
Trends Biotechnol. 2019 Oct;37(10):1032-1036
pubmed: 31153633
Wound Repair Regen. 2019 Jan;27(1):114-125
pubmed: 30362646
Biomed Res Int. 2021 Feb 16;2021:6613783
pubmed: 33644228
Pharmaceutics. 2021 Oct 27;13(11):
pubmed: 34834211

Auteurs

Cristina Del Amo (C)

Regenerative Therapies, Bioprinting Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, 48903 Barakaldo, Spain.

Xabier Fernández-San Argimiro (X)

TECNALIA, Basque Research and Technology Alliance (BRTA), 20009 Donostia-San Sebastian, Spain.

María Cascajo-Castresana (M)

TECNALIA, Basque Research and Technology Alliance (BRTA), 20009 Donostia-San Sebastian, Spain.

Arantza Perez-Valle (A)

Regenerative Therapies, Bioprinting Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, 48903 Barakaldo, Spain.

Iratxe Madarieta (I)

TECNALIA, Basque Research and Technology Alliance (BRTA), 20009 Donostia-San Sebastian, Spain.

Beatriz Olalde (B)

TECNALIA, Basque Research and Technology Alliance (BRTA), 20009 Donostia-San Sebastian, Spain.

Isabel Andia (I)

Regenerative Therapies, Bioprinting Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, 48903 Barakaldo, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH